Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
4 raisons identifiées
Plateau technique de référence
Assistance publique – Hôpitaux de Paris (APHP) — équipements et expertise pointus pour les cas complexes
Auteur de référence en rhumatologie
24 articles scientifiques publiés — un praticien à la pointe de la recherche
Disponibilité géographique
3 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
336.2 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
GHU APHP SUN SITE PITIE SALPETRIERE
47-83 47 BD DE L HOPITAL, 75651 PARIS CEDEX 13
CABINET DU DR BRUNO GIGLIO
S O S MEDECINS 87 BOULEVARD DE PORT ROYAL, 75013 PARIS
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
CABINET DU DR BRUNO GIGLIO
128 BOULEVARD MACDONALD, 75019 PARIS
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2007
ABSTRACT Genome‐wide gene expression profiling of skeletal muscle from Duchenne muscular dystrophy (DMD) patients has been used to describe muscle tissue alterations in DMD children older than 5 years. By studying the expression profile of 19 patients younger than 2 years, we describe with high resolution the gene expression signature that characterizes DMD muscle during the initial or “presymptomatic” phase of the disease. We show that in the first 2 years of the disease, DMD muscle is already set to express a distinctive gene expression pattern considerably different from the one expressed by normal, age‐matched muscle. This “dys‐trophic” molecular signature is characterized by a coordinate induction of genes involved in the inflammatory response, extracellular matrix (ECM) remodeling and muscle regeneration, and the reduced transcription of those involved in energy metabolism. Despite the lower degree of muscle dysfunction experienced, our younger patients showed abnormal expression of most of the genes reported as differentially expressed in more advanced stages of the disease. By analyzing our patients as a time series, we provide evidence that some genes, including members of three pathways involved in morphogenetic signaling—Wnt, Notch, and BMP— are progressively induced or repressed in the natural history of DMD.—Pescatori, M., Broccolini, A., Minetti, C., Bertini, E., Bruno, C., D'amico, A., Bernardini, C., Mirabella, M., Silvestri, G., Giglio, V., Modoni, A., Pedemonte, M., Tasca, G., Galluzzi, G., Mercuri, E., Tonali, P. A., Ricci, E. Gene expression profiling in the early phases of DMD: a constant molecular signature characterizes DMD muscle from early postnatal life throughout disease progression. FASEB J. 21, 1210–1226 (2007)
Expert opinion on investigational drugs · 2022
Frontiers in neurology · 2022
Neuropsychiatric or behavioral and psychological symptoms of dementia (BPSD) represent a heterogeneous group of non-cognitive symptoms that are virtually present in all patients during the course of their disease. The aim of this study is to examine the prevalence and natural history of BPSD in a large cohort of patients with behavioral variant of frontotemporal dementia (bvFTD) and Alzheimer's disease (AD) in three stages: (i) pre-T0 (before the onset of the disease); (ii) T0 or manifested disease (from the onset to 5 years); (iii) T1 or advanced (from 5 years onwards). Six hundred seventy-four clinical records of patients with bvFTD and 1925 with AD, from 2006 to 2018, were studied. Symptoms have been extracted from Neuropsychiatric Inventory (NPI) and from a checklist of BPSD for all periods observed. In our population, BPSD affect up to 90% of all dementia subjects over the course of their illness. BPSD profiles of the two dementia groups were similar but not identical. The most represented symptoms were apathy, irritability/affective lability, and agitation/aggression. Considering the order of appearance of neuropsychiatric symptoms in AD and bvFTD, mood disorders (depression, anxiety) come first than the other BPSD, with the same prevalence. This means that they could be an important “red flag” in detection of dementia. With the increase of disease severity, aberrant motor behavior and wandering were significantly more present in both groups. Differences between BPSD in AD and bvFTD resulted only in prevalence: Systematically, in bvFTD, all the symptoms were more represented than in AD, except for hallucinations, depression, anxiety, and irritability. Given their high frequency and impact on management and overall health care resources, BPSD should not be underestimated and considered as an additional important diagnostic and therapeutic target both in patients with AD and bvFTD.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Haematologica · 2024 · Journal Article
Kayser S, Sartor C, Giglio F, Bruno A, et al.
Bone marrow transplantation · 2022 · Journal Article
Lazzari L, Balaguer-Roselló A, Montoro J, Greco R, et al.
Bone marrow transplantation · 2022 · Clinical Trial
Bonifazi F, Pavoni C, Peccatori J, Giglio F, et al.
Expert opinion on investigational drugs · 2022 · Journal Article
Di Federico A, Rizzo A, Carloni R, De Giglio A, et al.
Journal of clinical medicine · 2022 · Journal Article
Xue E, Lorentino F, Lupo Stanghellini MT, Giglio F, et al.
Internal and emergency medicine · 2020 · Journal Article
Cupisti A, Bruno RM, Puntoni A, Varricchio E, et al.
Bone marrow transplantation · 2017 · Journal Article
Todisco E, Ciceri F, Boschini C, Giglio F, et al.
Journal of neuroinflammation · 2014 · Journal Article
Grimaldi LM, Zappalà G, Iemolo F, Castellano AE, et al.
Medical mycology · 2010 · Case Reports
Giglio M, Caggiano G, De Blasi R, Brienza N, et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2007 · Journal Article
Pescatori M, Broccolini A, Minetti C, Bertini E, et al.
Physical review letters · 2013 · Journal Article
Abelev B, Adam J, Adamová D, Adare AM, et al.
Physical review letters · 2013 · Journal Article
Abelev B, Adam J, Adamová D, Adare AM, et al.
Physical review letters · 2013 · Journal Article
Abelev B, Adam J, Adamová D, Adare AM, et al.
Frontiers in neurology · 2022 · Journal Article
Laganà V, Bruno F, Altomari N, Bruni G, et al.
European journal of nuclear medicine and molecular imaging · 2021 · Journal Article
Albano D, Bertagna F, Alongi P, Baldari S, et al.
Haematologica · 2024 · Journal Article
Ruggeri A, Corrado F, Voza A, Wei LJ, et al.
Biomedicines · 2023 · Journal Article
Patti AM, Giglio RV, Allotta A, Bruno A, et al.
Frontiers in immunology · 2023 · Case Reports
Oltolini C, Acerbis A, Orofino G, Racca S, et al.
Frontiers in oncology · 2022 · Case Reports
Giglio F, Campodonico E, Lorentino F, Noviello M, et al.
Haematologica · 2024 · Journal Article
Ruggeri A, Corrado F, Voza A, Wei LJ, et al.
Critical care (London, England) · 2012 · Journal Article
Giglio M, Caggiano G, Dalfino L, Brienza N, et al.
Neurology international · 2025 · Journal Article
Iacono S, Gagliardo C, Iacopino DG, Schirò G, et al.
Physical review letters · 2013 · Journal Article
Abelev B, Adam J, Adamová D, Adare AM, et al.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2019 · Clinical Trial
Candoni A, Rambaldi A, Fanin R, Velardi A, et al.
Panminerva medica · 2018 · Journal Article
Cupisti A, Ghiadoni L, Zullo C, Marchini M, et al.